CHASE WILLIAM J — SEC Form 4 filings
SEC reporting owner CIK 1563572. 16 Form 4 filings on record with FilingPulse; latest filed 2026-07-16.
Transaction summary — filings shown
Covers all 16 filings on record, filed 2024-06-14 to 2026-07-16. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 100,000 shares, $1,003,000 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 18.
- Largest priced transaction: purchase of 100,000 shares @ $10.03 ($1,003,000) in Intellia Therapeutics, Inc., filed 2025-08-22.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Intellia Therapeutics, Inc. (NTLA) | Director | 4 | 1 leg · 100,000 sh · $1,003,000 | — | 6 |
| GRAIL, Inc. (GRAL) | Director | 12 | — | — | 12 |
Form 4 filings — CHASE WILLIAM J
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-16 | 4 | GRAIL, Inc. (GRAL) | Grant/award (A): 276 @ $74.36 | EDGAR |
| 2026-06-22 | 4 | GRAIL, Inc. (GRAL) | Grant/award (A): 5,491 @ $63.74 | EDGAR |
| 2026-06-10 | 4 | Intellia Therapeutics, Inc. (NTLA) | Grant/award (A): 9,200 @ $0 · Grant/award (A): 13,300 (derivative) @ $0 | EDGAR |
| 2026-04-17 | 4 | GRAIL, Inc. (GRAL) | Grant/award (A): 408 @ $49.79 | EDGAR |
| 2026-01-16 | 4 | GRAIL, Inc. (GRAL) | Grant/award (A): 213 @ $97.44 | EDGAR |
| 2025-10-16 | 4 | GRAIL, Inc. (GRAL) | Grant/award (A): 275 @ $75.52 | EDGAR |
| 2025-08-22 | 4 | Intellia Therapeutics, Inc. (NTLA) | Purchase (P): 100,000 @ $10.03 | EDGAR |
| 2025-07-17 | 4 | GRAIL, Inc. (GRAL) | Grant/award (A): 533 @ $38.53 | EDGAR |
| 2025-06-13 | 4 | Intellia Therapeutics, Inc. (NTLA) | Grant/award (A): 8,000 @ $0 · Grant/award (A): 11,450 (derivative) @ $0 | EDGAR |
| 2025-05-30 | 4 | GRAIL, Inc. (GRAL) | Grant/award (A): 6,082 @ $41.10 | EDGAR |
| 2025-04-16 | 4 | GRAIL, Inc. (GRAL) | Grant/award (A): 784 @ $25.94 | EDGAR |
| 2025-01-16 | 4 | GRAIL, Inc. (GRAL) | Grant/award (A): 1,182 @ $17.58 | EDGAR |
| 2024-11-01 | 4 | GRAIL, Inc. (GRAL) | Grant/award (A): 210 @ $13.62 | EDGAR |
| 2024-10-17 | 4 | GRAIL, Inc. (GRAL) | Grant/award (A): 1,054 @ $14.01 | EDGAR |
| 2024-06-27 | 4 | GRAIL, Inc. (GRAL) | Grant/award (A): 26,470 @ $0 | EDGAR |
| 2024-06-14 | 4 | Intellia Therapeutics, Inc. (NTLA) | Grant/award (A): 7,737 @ $0 · Grant/award (A): 11,515 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1563572 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →